The transcriptional role of PML and the nuclear body

The PML gene encodes a tumour suppressor protein associated with a distinct subnuclear domain, the nuclear body. Various functions have been attributed to the PML nuclear body, but its main biochemical role is still unclear. Recent findings indicate that PML is essential for the proper formation of the nuclear body and can act as a transcriptional co-factor. Here we summarize the current understanding of the biological functions of PML and the nuclear body, and discuss a role for these intra-nuclear structures in the regulation of transcription.

[1]  N. Stuurman,et al.  The t(15;17) translocation alters a nuclear body in a retinoic acid‐reversible fashion. , 1994, The EMBO journal.

[2]  R. Hay,et al.  SUMO‐1 modification activates the transcriptional response of p53 , 1999, The EMBO journal.

[3]  K. Umesono,et al.  Chromosomal translocation t(15;17) in human acute promyelocytic leukemia fuses RARα with a novel putative transcription factor, PML , 1991, Cell.

[4]  V. Ogryzko,et al.  Regulation of activity of the transcription factor GATA-1 by acetylation , 1998, Nature.

[5]  G. Shaw,et al.  Human Papillomavirus DNA Replication Compartments in a Transient DNA Replication System , 1999, Journal of Virology.

[6]  R. Evans,et al.  A novel macromolecular structure is a target of the promyelocyte-retinoic acid receptor oncoprotein , 1994, Cell.

[7]  A. Dejean,et al.  Conjugation with the ubiquitin‐related modifier SUMO‐1 regulates the partitioning of PML within the nucleus , 1998, The EMBO journal.

[8]  Maria Carmo-Fonseca,et al.  Retinoic acid regulates aberrant nuclear localization of PML-RARα in acute promyelocytic leukemia cells , 1994, Cell.

[9]  M. Koken,et al.  PML induces a novel caspase-independent death process , 1998, Nature Genetics.

[10]  J. Larghero,et al.  Alteration of the PML proto-oncogene in leukemic cells does not abrogate expression of MHC class I antigens , 1999, Leukemia.

[11]  John Calvin Reed,et al.  Human Daxx regulates Fas‐induced apoptosis from nuclear PML oncogenic domains (PODs) , 1999, The EMBO journal.

[12]  A. Dejean,et al.  PML nuclear bodies are general targets for inflammation and cell proliferation. , 1995, Cancer research.

[13]  R. Tjian,et al.  Composite co-activator ARC mediates chromatin-directed transcriptional activation , 1999, Nature.

[14]  L. Szekely,et al.  The Epstein-Barr virus-encoded nuclear antigen EBNA-5 accumulates in PML-containing bodies , 1996, Journal of virology.

[15]  P. Freemont,et al.  PIC 1, a novel ubiquitin-like protein which interacts with the PML component of a multiprotein complex that is disrupted in acute promyelocytic leukaemia. , 1996, Oncogene.

[16]  J. Hershey,et al.  The Translation Initiation Factor eIF3-p48 Subunit Is Encoded byint-6, a Site of Frequent Integration by the Mouse Mammary Tumor Virus Genome* , 1997, The Journal of Biological Chemistry.

[17]  M. Montminy,et al.  Role of CBP/P300 in nuclear receptor signalling , 1996, Nature.

[18]  T. Kouzarides,et al.  Transcriptional repression by the promyelocytic leukemia protein, PML. , 1997, Experimental cell research.

[19]  A. Dejean,et al.  Viral Immediate-Early Proteins Abrogate the Modification by SUMO-1 of PML and Sp100 Proteins, Correlating with Nuclear Body Disruption , 1999, Journal of Virology.

[20]  P. Freemont,et al.  The RING finger domain: a recent example of a sequence-structure family. , 1996, Current opinion in structural biology.

[21]  A. Dejean,et al.  Interaction of SP100 with HP1 proteins: a link between the promyelocytic leukemia-associated nuclear bodies and the chromatin compartment. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[22]  T. Pozzan,et al.  Cooperation between the RING+B1-B2 and coiled-coil domains of PML is necessary for its effects on cell survival , 1998, Oncogene.

[23]  Jennifer O'Neil,et al.  Sequestration and Inhibition of Daxx-Mediated Transcriptional Repression by PML , 2000, Molecular and Cellular Biology.

[24]  N. Ellis,et al.  Molecular genetics of Bloom's syndrome. , 1996, Human molecular genetics.

[25]  H. de Thé,et al.  Resistance to Virus Infection Conferred by the Interferon-Induced Promyelocytic Leukemia Protein , 1998, Journal of Virology.

[26]  H. Will,et al.  IFN enhance expression of Sp100, an autoantigen in primary biliary cirrhosis. , 1992, Journal of immunology.

[27]  P. Pandolfi,et al.  Role of PML in cell growth and the retinoic acid pathway. , 1998, Science.

[28]  R. Evans,et al.  Human T-cell leukemia retrovirus-Tax protein is a repressor of nuclear receptor signaling. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[29]  H. Busch.  The Cell Nucleus , 1966, Nature.

[30]  Jonathan D. Licht,et al.  Deconstructing a Disease: RAR, Its Fusion Partners, and Their Roles in the Pathogenesis of Acute Promyelocytic Leukemia , 1999 .

[31]  P. Pandolfi,et al.  The acute promyelocytic leukaemia-associated PML gene is induced by interferon. , 1995, Oncogene.

[32]  G. Blobel,et al.  SUMO-1 Modification and Its Role in Targeting the Ran GTPase-activating Protein, RanGAP1, to the Nuclear Pore Complex , 1998, The Journal of cell biology.

[33]  R. Everett,et al.  A novel ubiquitin‐specific protease is dynamically associated with the PML nuclear domain and binds to a herpesvirus regulatory protein , 1997, The EMBO journal.

[34]  François-Michel Boisvert,et al.  Promyelocytic Leukemia (Pml) Nuclear Bodies Are Protein Structures That Do Not Accumulate RNA , 2000, The Journal of cell biology.

[35]  A. Hengstermann,et al.  Activation of p53 by conjugation to the ubiquitin‐like protein SUMO‐1 , 1999, The EMBO journal.

[36]  A. Dejean,et al.  Molecular Cloning of a New Interferon-induced PML Nuclear Body-associated Protein* , 1997, The Journal of Biological Chemistry.

[37]  S. M. de la Monte,et al.  Identification and Characterization of a Leukocyte-specific Component of the Nuclear Body* , 1996, The Journal of Biological Chemistry.

[38]  Paul Tempst,et al.  Ligand-dependent transcription activation by nuclear receptors requires the DRIP complex , 1999, Nature.

[39]  J. Sobczak-Thépot,et al.  The PML growth-suppressor has an altered expression in human oncogenesis. , 1995, Oncogene.

[40]  Andrew J. Bannister,et al.  The CBP co-activator is a histone acetyltransferase , 1996, Nature.

[41]  J. Trowsdale,et al.  A novel gysteine-rich sequence motif , 1991, Cell.

[42]  Christine Chomienne,et al.  The PML-RARα fusion mRNA generated by the t(15;17) translocation in acute promyelocytic leukemia encodes a functionally altered RAR , 1991, Cell.

[43]  M. King,et al.  Insights into the functions of BRCA1 and BRCA2. , 2000, Trends in genetics : TIG.

[44]  E. Lane,et al.  An inhibitor of nuclear export activates the p53 response and induces the localization of HDM2 and p53 to U1A-positive nuclear bodies associated with the PODs. , 1999, Experimental cell research.

[45]  G. Lozano,et al.  PML, a growth suppressor disrupted in acute promyelocytic leukemia , 1994, Molecular and cellular biology.

[46]  E. Yeh,et al.  Differential Regulation of Sentrinized Proteins by a Novel Sentrin-specific Protease* , 2000, The Journal of Biological Chemistry.

[47]  P. Pandolfi,et al.  In vivo analysis of the molecular pathogenesis of acute promyelocytic leukemia in the mouse and its therapeutic implications , 1999, Oncogene.

[48]  D. Levy,et al.  Proto-oncogene PML controls genes devoted to MHC class I antigen presentation , 1998, Nature.

[49]  M. Ptashne,et al.  Chromatin components as part of a putative transcriptional repressing complex. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[50]  G. Maul.  Nuclear domain 10, the site of DNA virus transcription and replication , 1998, BioEssays : news and reviews in molecular, cellular and developmental biology.

[51]  Y. Xiong,et al.  Mutations in human ARF exon 2 disrupt its nucleolar localization and impair its ability to block nuclear export of MDM2 and p53. , 1999, Molecular cell.

[52]  T. Sternsdorf,et al.  The Nuclear Dot Protein Sp100, Characterization of Domains Necessary for Dimerization, Subcellular Localization, and Modification by Small Ubiquitin-like Modifiers* , 1999, The Journal of Biological Chemistry.

[53]  E. Brignole,et al.  Disruption of PML Subnuclear Domains by the Acidic IE1 Protein of Human Cytomegalovirus Is Mediated through Interaction with PML and May Modulate a RING Finger-Dependent Cryptic Transactivator Function of PML , 1998, Molecular and Cellular Biology.

[54]  P. Pandolfi,et al.  Pml is essential for multiple apoptotic pathways , 1998, Nature Genetics.

[55]  T. Kouzarides,et al.  Modulation of Fos-mediated AP-1 transcription by the promyelocytic leukemia protein , 1998, Oncogene.

[56]  M. Hochstrasser,et al.  A new protease required for cell-cycle progression in yeast , 1999, Nature.

[57]  P. Pandolfi,et al.  Acute promyelocytic leukemia as a model for cross-talk between interferon and retinoic acid pathways: from molecular biology to clinical applications. , 1998, Leukemia & lymphoma.

[58]  R. Everett,et al.  A viral activator of gene expression functions via the ubiquitin–proteasome pathway , 1998, The EMBO journal.

[59]  T. Sternsdorf,et al.  Evidence for Covalent Modification of the Nuclear Dot–associated Proteins PML and Sp100 by PIC1/SUMO-1 , 1997, The Journal of cell biology.

[60]  P. Pandolfi,et al.  Promyelocytic Leukemia Protein (Pml) and Daxx Participate in a Novel Nuclear Pathway for Apoptosis , 2000, The Journal of experimental medicine.

[61]  A. Dejean,et al.  Viral Immediate-Early Proteins Abrogate the Modification by SUMO-1 of PML and Sp100 Proteins, Correlating with Nuclear Body Disruption , 1999, Journal of Virology.

[62]  G. Maul,et al.  The periphery of nuclear domain 10 (ND10) as site of DNA virus deposition , 1996, The Journal of cell biology.

[63]  R. Everett,et al.  The Ability of Herpes Simplex Virus Type 1 Immediate-Early Protein Vmw110 To Bind to a Ubiquitin-Specific Protease Contributes to Its Roles in the Activation of Gene Expression and Stimulation of Virus Replication , 1999, Journal of Virology.

[64]  W. Zhang,et al.  Acetylation and modulation of erythroid Krüppel-like factor (EKLF) activity by interaction with histone acetyltransferases. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[65]  G. Hayward,et al.  The major immediate-early proteins IE1 and IE2 of human cytomegalovirus colocalize with and disrupt PML-associated nuclear bodies at very early times in infected permissive cells , 1997, Journal of virology.

[66]  P. Pandolfi,et al.  A RA-dependent, tumour-growth suppressive transcription complex is the target of the PML-RARα and T18 oncoproteins , 1999, Nature Genetics.

[67]  Steven E. Bayer,et al.  A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. , 1994, Science.

[68]  T. Sternsdorf,et al.  Nuclear dots: actors on many stages. , 1997, Immunobiology.

[69]  N. Ellis,et al.  The Bloom's syndrome gene product is homologous to RecQ helicases , 1995, Cell.

[70]  P. Chambon,et al.  Structure, localization and transcriptional properties of two classes of retinoic acid receptor alpha fusion proteins in acute promyelocytic leukemia (APL): structural similarities with a new family of oncoproteins. , 1992, The EMBO journal.

[71]  K. Borden,et al.  The promyelocytic leukemia (PML) protein suppresses cyclin D1 protein production by altering the nuclear cytoplasmic distribution of cyclin D1 mRNA , 2000, Oncogene.

[72]  P. Chambon,et al.  PMLRAR homodimers: distinct DNA binding properties and heteromeric interactions with RXR. , 1993, The EMBO journal.

[73]  R. Evans,et al.  Localization of nascent RNA and CREB binding protein with the PML-containing nuclear body. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[74]  H. Saitoh,et al.  Functional Heterogeneity of Small Ubiquitin-related Protein Modifiers SUMO-1 versus SUMO-2/3* , 2000, The Journal of Biological Chemistry.

[75]  P. Pandolfi,et al.  A role for PML and the nuclear body in genomic stability , 1999, Oncogene.

[76]  Peirong Yang,et al.  Analysis of the Growth and Transformation Suppressor Domains of Promyelocytic Leukemia Gene, PML(*) , 1996, The Journal of Biological Chemistry.

[77]  E. Yeh,et al.  Identification of Three Major Sentrinization Sites in PML* , 1998, The Journal of Biological Chemistry.

[78]  J. Vonesch,et al.  The putative nuclear receptor mediator TIF1alpha is tightly associated with euchromatin. , 1999, Journal of cell science.

[79]  E. Yeh,et al.  Pml Is Critical for Nd10 Formation and Recruits the Pml-Interacting Protein Daxx to This Nuclear Structure When Modified by Sumo-1 , 1999, The Journal of cell biology.

[80]  S. Orkin,et al.  CREB-binding protein cooperates with transcription factor GATA-1 and is required for erythroid differentiation. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[81]  P. Pandolfi,et al.  Role of SUMO-1-modified PML in nuclear body formation. , 2000, Blood.

[82]  R. Roeder,et al.  Ligand induction of a transcriptionally active thyroid hormone receptor coactivator complex. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[83]  K. Howe,et al.  Structure, organization, and dynamics of promyelocytic leukemia protein nuclear bodies. , 1998, American journal of human genetics.

[84]  C. Ascoli,et al.  Identification of a novel nuclear domain , 1991, The Journal of cell biology.

[85]  P. Pelicci,et al.  Structure and origin of the acute promyelocytic leukemia myl/RAR alpha cDNA and characterization of its retinoid-binding and transactivation properties. , 1991, Oncogene.

[86]  L. Szekely,et al.  The Promyelocytic Leukemia Gene Product (PML) Forms Stable Complexes with the Retinoblastoma Protein , 1998, Molecular and Cellular Biology.

[87]  K. Chang,et al.  The Promyelocytic Leukemia Protein Interacts with Sp1 and Inhibits Its Transactivation of the Epidermal Growth Factor Receptor Promoter , 1998, Molecular and Cellular Biology.

[88]  P. Freemont,et al.  Characterization of a zinc finger gene disrupted by the t(15;17) in acute promyelocytic leukemia. , 1991, Science.

[89]  R. Jaenisch,et al.  Association of the Bloom syndrome protein with topoisomerase IIIalpha in somatic and meiotic cells. , 2000, Cancer research.

[90]  K. Borden,et al.  The promyelocytic leukemia protein PML has a pro‐apoptotic activity mediated through its RING domain , 1997, FEBS letters.

[91]  R. Evans,et al.  Modulation of CREB binding protein function by the promyelocytic (PML) oncoprotein suggests a role for nuclear bodies in hormone signaling. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[92]  L. Szekely,et al.  Intranuclear redistribution of SV40T, p53, and PML in a conditionally SV40T-immortalized cell line. , 1996, Experimental cell research.

[93]  E. Milgrom,et al.  Effect of PML and PML-RAR on the transactivation properties and subcellular distribution of steroid hormone receptors. , 1995, Molecular endocrinology.

[94]  A. Saïb,et al.  Transcriptional induction of the PML growth suppressor gene by interferons is mediated through an ISRE and a GAS element. , 1995, Oncogene.

[95]  U. Scheer,et al.  The nucleolus. , 1994, Current opinion in cell biology.